Table 1.
Studies investigating potential new non-surgical treatment options in knee OA (modified and updated from21)
| Treatment option | Studies | Comments |
|---|---|---|
| DMOADs targeting cartilage | Intra-articular recombinant human fibroblast growth factor 18 (NCT01919164) | Proanabolic growth factor |
| Intra-articular TPX-100 (NCT1925261) | Chondrogenic peptide | |
| DMOADs targeting bone | Oral strontium ranelate25–27 | Remodelling of subchondral bone and articular cartilage |
| DMOADs targeting synovitis | Oral hydroxychloroqine and atorvastatin (NCT01645176) | A combination of a DMARD with a statin |
| Oral methotrexate (NCT01654575) | A DMARD | |
| Oral SD-6010 (Cindunistat)28 | Selective inhibitor of inducible nitric oxide synthase | |
| Subcutaneous ABT-981 (NCT01668511) | Monoclonal antihuman interleukin-1 α/β antibody | |
| Oral PRX167700 (NCT01945346) | Vascular adhesion protein-1 antagonist | |
| Treatments targeting pain | Tanezumab29 | Antinerve growth factor inhibitor |
| CG100649 (NCT1765296) | Dual inhibitor of carbonic anhydrase and COX-2 | |
| AKR 202 (NCT02003118) | Small molecule purinergic receptor modulator and enzyme inhibitor | |
| Cell-based therapies | Allogenic mesenchymal stem cells (NCT01586312, NCT01985633, NCT01459640) | Induction of interactive biological repair mechanisms involving stem cells |
| Mesenchymal trophic factor (NCT02003131) | ||
| Autologous adipose derived stem cells (NCT01585857) |
The NCT identification number refers to trials registered in ClinicalTrials.gov (http://clinicaltrials.gov) where more in detail information can be obtained.
DMOAD, disease-modifying antiosteoarthritic drug; DMARD, disease-modifying antirheumatic drug; OA, osteoarthritis.